Public Health Policy on COVID-19 Childhood Vaccination is Based in Part on Severely Biased Data on MIS-C

—

by

Contributor
in

by James Lyons-Weiler, PhD, Popular Rationalism, ©2025 

https://archive.cdc.gov/#/details?url=https://www.cdc.gov/mis/mis-c/hcp/index.html

(Apr. 25, 2025) — According to the U.S. Centers for Disease Control and Prevention (CDC), MIS-C is defined as a clinically severe illness requiring hospitalization in individuals <21 years of age who present with:

  1. Fever ≥38.0°C for ≥24 hours,
  2. Laboratory evidence of inflammation (e.g., elevated CRP, ESR, fibrinogen, etc.),
  3. Multisystem (≥2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic, or neurological),
  4. No alternative plausible diagnosis, and
  5. Evidence of recent or current SARS-CoV-2 infection (positive RT-PCR, antigen, or serology) or exposure to a suspected or confirmed COVID-19 case within 4 weeks prior to symptom onset.

(Source: CDC MIS-C Clinical Guidance)

Origins of MIS-C Based on Weak Association

MIS-C was first described in April–May 2020 in two early case series from the United Kingdom (RCPCH) and New York State. Notably:

  • In both reports, a significant number of children had no detectable evidence of SARS-CoV-2 infection via PCR or serology at the time of diagnosis.
  • The New York State Department of Health report described 102 pediatric cases, 29% of whom had neither a positive RT-PCR nor antibody test at time of hospitalization (Feldstein et al., 2020).
  • Similarly, the Royal College of Paediatrics and Child Health (RCPCH) report flagged a “Kawasaki-like disease” in children—with no requirement for SARS-CoV-2 positivity to make the diagnosis.

This early inclusion of seronegative and PCR-negative cases set a concerning precedent: it decoupled MIS-C from laboratory-confirmed infection, allowing the condition to be defined in part by temporal association and clinical gestalt, rather than direct virologic evidence.

Two widely cited reports—one from the CDC’s Morbidity and Mortality Weekly Report (MMWR) and another published in JAMA—have asserted that COVID-19 vaccination significantly reduces the risk of Multisystem Inflammatory Syndrome in Children (MIS-C). The CDC study estimated that two doses of the Pfizer-BioNTech vaccine were 91% effective at preventing MIS-C in adolescents aged 12–18 years during the Delta variant period​. Meanwhile, the JAMA letter by Levy et al. claimed a marked reduction in MIS-C incidence among vaccinated French adolescents, reporting that none of the hospitalized MIS-C cases had been fully vaccinated​. However, both studies rely on design choices and statistical assumptions that merit close scrutiny. Given the biases, it must be concluded that they do not represent strong evidence on the question of pediatric public health policies that effect billions of children.

Read the rest here.